BioElectronics RecoveryRx Approved for Surgical Recovery and Chronic Wounds in Canada

FREDERICK, Md., May 15, 2012 /PRNewswire/ -- BioElectronics Corporation (OTC-PINK: BIEL), the maker of disposable, inexpensive, drug-free topical pain and healing devices, announces that the Therapeutic Products Directorate, Medical Devices Bureau of Health Canada has issued a Class II License for the RecoveryRx™ Post-Surgical and Wound Care Recovery product.  The license means that the product can be sold Over-the-Counter (OTC) in Canada.  RecoveryRx uses pulsed electromagnetic field therapy to reduce pain and inflammation and promote healing of injured tissue.

"We are pleased that Health Canada has recognized both the safety and effectiveness of RecoveryRx by issuing this Class II license.  RecoveryRx provides a convenient, non-invasive, safe and effective therapy to improve healing and reduce pain without the use of dangerous and potentially addictive narcotic medications," said Andrew Whelan, CEO of BioElectronics.

The market potential for RecoveryRx as a post-surgical recovery therapy is significant.  Clinically shown to improve healing, reduce the need for narcotic pain medications, reduce scarring and reduce wound breakage, the post-surgical application of RecoveryRx will reduce overall post-surgical complication rates. RecoveryRx is an appropriate therapy for treating pain and inflammation after oral, joint replacement, hernia repair, cosmetic and general surgeries.  It is expected that women who have had cesarean sections who wish to avoid narcotic use in order to safely breast feed their infants will embrace the use of the therapy.

Even more profound is RecoveryRx's potential impact on diabetic wound treatment and prevention. According to the Canadian Diabetes Association there are more than 9 million Canadians currently living with diabetes or pre-diabetes.  It is well known that foot ulcers and wounds are one of the most devastating complications of diabetes.  Case studies show that RecoveryRx is effective at healing chronic wounds, and unlike advanced wound therapies, it has a low cost which means that it can be applied, not just to existing stalled wounds, but as a first choice therapy to preclude the degradation of a developing wound.  Providing a minimum of 7 days of therapy, RecoveryRx can be easily and seamlessly incorporated into wound dressing protocols.  It is certain that the use of RecoveryRx will dramatically reduce costs and time to heal chronic wounds.  Currently the Canadian Wound Association estimates the average time and expense to heal a chronic wound to be 165 days and $10,376 per instance. "We look forward to demonstrating to both the patients and the national health care system, and ultimately all Canadians, how our low cost RecoveryRx device provides effective management and prevention of chronic wounds and will significantly reduce the substantial financial costs of wound treatment," said Andrew Whelan.

About BioElectronics Corporation
BioElectronics is an award winning developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal ailments, the Allay™ Menstrual Cycle Pain Therapy, and RecoveryRx™ for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and swelling. For more information, please see www.bielcorp.com.

Contact:  E & E Communications
Paul Knopick
(949) 707-5365

SOURCE BioElectronics Corporation